An Evening With the Experts: Discussion on the Evolving Immunotherapy Paradigm for NSCLC

Join us live in Chicago or via simulcast for this 2-hour, live interactive CME-certified symposium featuring expert discussion of the latest clinical data informing optimal use of immunotherapy across the spectrum of NSCLC in the context of patient cases. This event will offer attendees the opportunity to have their questions answered by the expert faculty. Register now!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.


  • Welcome and Introduction
  • Overview of Immunotherapy in Nonmetastatic NSCLC –  Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
  • Evolving Role of Immunotherapy in Advanced or Metastatic NSCLCJulie Brahmer, MD, MSc
  • Immunotherapy for Special Populations and Future DirectionsJarushka Naidoo, MB BCH BAO, MHS
  • Final Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Julie R. Brahmer, MD

Professor of Oncology
Upper Aerodigestive Cancer Program
Department of Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Natasha B. Leighl, MD, MMSC, FRCPC, FASCO

Department of Medicine
University of Toronto
Lung Site Lead
Department of Medical Oncology and Hematology
Princess Margaret Cancer Centre
Toronto, Ontario, Canada

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Assistant Professor
Department of Oncology
Johns Hopkins University
Baltimore, Maryland

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in integrating immunotherapies into treatment plans for patients with NSCLC.

Target Audience
This educational program is intended for medical oncologists, and other healthcare professionals who treat patients with NSCLC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor–based therapy in NSCLC, specifically their relevance in treatment selection in early and advanced disease settings
  • Select optimal first-line immune checkpoint inhibitor–based combinations for patients with advanced or metastatic NSCLC
  • Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy
  • Incorporate investigational checkpoint inhibitors and clinical trial participation as part of therapeutic strategies for patients with NSCLC
  • Address factors that can influence response to immune checkpoint inhibitor therapy in individual patients with NSCLC


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.